Harald Arnesen
Papers
1
Total Citations
22
H-Index
1
About
Dr. Harald Arnesen is a distinguished cardiovascular researcher whose work has fundamentally shaped our understanding of antithrombotic therapy and genetic influences on drug metabolism. His primary research areas include warfarin pharmacogenetics, myocardial infarction management, and the interplay between genetic variants and clinical outcomes in cardiovascular disease. Dr. Arnesen’s major contribution lies in elucidating how polymorphisms in the CYP2C9 and VKORC1 genes predict warfarin dose requirements and INR stability, a finding that has direct implications for personalized medicine. His landmark 2008 study, cited 22 times, demonstrated that genetic testing could significantly reduce the risk of over- or under-anticoagulation in patients with myocardial infarction, paving the way for genotype-guided dosing protocols. Beyond this, his work has informed clinical guidelines for safer, more effective anticoagulation. Dr. Arnesen’s research bridges the gap between molecular genetics and bedside practice, offering a compelling example of how genomic insights can optimize treatment for complex conditions. His contributions remain a cornerstone for students and researchers exploring precision medicine in cardiovascular care.
Research Focus
Key Achievements
Top Papers
- 1